Thomas Michael Tamberrino Buys 13,908 Shares of Profound Medical (TSE:PRN) Stock

Profound Medical Corp. (TSE:PRN) insider Thomas Michael Tamberrino bought 13,908 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The stock was acquired at an average price of C$9.91 per share, for a total transaction of C$137,828.28. Following the purchase, the insider directly owned 39,241 shares in the company, valued at approximately C$388,878.31. The trade was a 54.90% increase in their ownership of the stock.

Profound Medical Stock Performance

PRN stock opened at C$10.78 on Monday. The company has a quick ratio of 14.98, a current ratio of 6.12 and a debt-to-equity ratio of 20.05. The firm has a market cap of C$391.24 million, a PE ratio of -8.17 and a beta of 1.19. The business has a 50 day moving average of C$10.11 and a 200-day moving average of C$8.34. Profound Medical Corp. has a 12-month low of C$5.23 and a 12-month high of C$12.40.

Profound Medical (TSE:PRN) last posted its quarterly earnings data on Thursday, November 13th. The company reported C$0.26 earnings per share for the quarter. The business had revenue of C$7.36 million for the quarter. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%. As a group, sell-side analysts expect that Profound Medical Corp. will post -1.9000001 earnings per share for the current year.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.